This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.
Renal Cell Carcinoma
Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.
A 38-year-old man presents with hematuria. A kidney mass is detected by imaging. Based on the shown biopsy, what is your diagnosis?
Japanese drug maker Eisai announced that the multiple kinase inhibitor lenvatinib, alone and in combination with everolimus, has been shown to prolong progression-free survival (PFS) in patients with unresectable advanced or metastatic renal cell carcinoma (mRCC).
A 67-year-old man presents with hematuria and a kidney mass found on imaging. After further evaluation, a biopsy is performed. What is your diagnosis?
For patients with metastatic clear cell renal cell carcinoma (mccRCC), administering a sequential, second-line tyrosine kinase inhibitor (TKI) may be more beneficial over a mammalian target of rapamycin inhibitor (mTORi).
Researchers have uncovered a novel way to potentially target clear cell renal cell carcinoma (ccRCC), a predominantly incurable disease for which patients have limited treatment options.
A full-term infant presents with abdominal distention and enlarged kidneys. After further evaluation, a biopsy is performed. What is your diagnosis?
An external validation study has confirmed that biomarkers of the mTOR pathway have prognostic value in patients with clear cell renal cell carcinoma.
In patients with non–clear cell RCC, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.